SG11201706824TA - Crystalline forms of a pyrrolopyridine compound - Google Patents

Crystalline forms of a pyrrolopyridine compound

Info

Publication number
SG11201706824TA
SG11201706824TA SG11201706824TA SG11201706824TA SG11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA SG 11201706824T A SG11201706824T A SG 11201706824TA
Authority
SG
Singapore
Prior art keywords
crystalline forms
pyrrolopyridine compound
pyrrolopyridine
compound
crystalline
Prior art date
Application number
SG11201706824TA
Other languages
English (en)
Inventor
Jeffrey Stults
Christopher M Lindemann
Keith L Spencer
Weidong Liu
Joseph Lubach
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706824T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of SG11201706824TA publication Critical patent/SG11201706824TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201706824TA 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound SG11201706824TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
SG11201706824TA true SG11201706824TA (en) 2017-09-28

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706824TA SG11201706824TA (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Country Status (21)

Country Link
US (2) US20160251350A1 (https=)
EP (1) EP3262042A1 (https=)
JP (1) JP2018506562A (https=)
KR (1) KR20170118762A (https=)
CN (1) CN107406447A (https=)
AR (1) AR103801A1 (https=)
AU (1) AU2016225070A1 (https=)
BR (1) BR112017018230A2 (https=)
CA (1) CA2976665A1 (https=)
CL (1) CL2017002180A1 (https=)
CO (1) CO2017009662A2 (https=)
CR (1) CR20170439A (https=)
HK (1) HK1246786A1 (https=)
IL (1) IL254115A0 (https=)
MA (1) MA41599A (https=)
MX (1) MX2017010888A (https=)
PE (1) PE20171327A1 (https=)
PH (1) PH12017501532A1 (https=)
RU (1) RU2017133093A (https=)
SG (1) SG11201706824TA (https=)
WO (1) WO2016138458A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
CL2017002180A1 (es) 2018-03-16
KR20170118762A (ko) 2017-10-25
HK1246786A1 (zh) 2018-09-14
PE20171327A1 (es) 2017-09-12
WO2016138458A1 (en) 2016-09-01
IL254115A0 (en) 2017-10-31
AR103801A1 (es) 2017-06-07
PH12017501532A1 (en) 2018-02-05
MA41599A (fr) 2018-01-02
AU2016225070A1 (en) 2017-09-07
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
BR112017018230A2 (pt) 2018-04-17
JP2018506562A (ja) 2018-03-08
EP3262042A1 (en) 2018-01-03
CR20170439A (es) 2018-01-08
MX2017010888A (es) 2017-12-15
RU2017133093A (ru) 2019-03-26
CN107406447A (zh) 2017-11-28
CO2017009662A2 (es) 2018-02-28
RU2017133093A3 (https=) 2019-08-23
CA2976665A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
IL263429A (en) Crystalline forms of a triazolopyrimidine compound
IL252843A0 (en) A process for preparing a diarylthiohydantoin compound
IL281292A (en) Processes for preparing a diarylthiohydantoin compound
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10201911417PA (en) Crystalline compounds
IL254530A0 (en) Preparation method of crystalline form a of pci-32765
GB201522771D0 (en) Crystalline form of a phosphate derivative
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3529236T3 (pl) Krystaliczne formy erawacykliny
IL253479A0 (en) Crystalline forms of efinconazole
ZA201606653B (en) Solid forms of a pharmaceutically active compound
IL259982A (en) Crystalline forms of thienopyrimidine compound
IL254115A0 (en) Crystalline forms of a pyrrolpyridine compound
ZA201607107B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
IL259981A (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds